Výsledky vyhledávání - "Dietrich Hadler"

A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer

Autor: Martin Sebastian, Dietrich Hadler, Maciej Krzakowski, Robert A. Beckman, Joachim von Pawel, Ewa Chmielowska, Jon Greenberg, Qiang Wang, Tara Fox, Martin Reck

Publikováno v: Lung Cancer. 82:441-448

Introduction Tigatuzumab, a humanized monoclonal DR5 agonist antibody induces apoptosis in human cancer cell lines. The objective of this study was to investigate the antitumor effects of tigatuzumab combined with carboplatin/paclitaxel in chemothera

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16f2b32de2f4fb380b363f0ddf73c527
https://doi.org/10.1016/j.lungcan.2013.09.014

Zobrazit plný text záznamu

Randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a new isoindoline derivative (DN-2327) in generalized anxiety

Autor: Dietrich Hadler, M. Linden, Stefan G. Hofmann

Publikováno v: Human Psychopharmacology: Clinical and Experimental. 12:445-452

Generalized anxiety disorders are frequent, chronic, and disabling illnesses for which so far ideal drug treatment is not available. A new promising anxiolytic drug is DN-2327, a non-benzodiazepine isoindoline derivative, which has shown in animals t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dbe3bf8f18789d796dcb9749709bde28
https://doi.org/10.1002/(sici)1099-1077(199709/10)12:5<445::aid-hup887>3.0.co

Zobrazit plný text záznamu

Alzheimer's Disease Assessment Scale: Reliability and Validity in a Multicenter Clinical Trial

Autor: Helmut Erzigkeit, Geerd Weyer, Siegried Kanowski, Dietrich Hadler, Ralf Ihl

Publikováno v: International Psychogeriatrics. 9:123-138

Psychometric characteristics of the Alzheimer's Disease Assessment Scale (ADAS) were examined on the basis of data from 440 patients with dementia of the Alzheimer type that were collected before treatment in a multicenter clinical drug trial. Coeffi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4b53426d4da729d7ac461f3bec7230b
https://doi.org/10.1017/s1041610297004298

Zobrazit plný text záznamu

Efficacy and safety of idebenone in the long-term treatment of Alzheimer's Disease: a double-blind, placebo controlled multicentre study

Autor: Helmut Erzigkeit, Stephan Kubicki, Dietrich Hadler, Geerd Weyer

Publikováno v: Human Psychopharmacology: Clinical and Experimental. 11:53-65

The efficacy and safety of idebenone were studied in a prospective, randomized, double-blind, placebo controlled multicentre study in 3 parallel groups of patients with dementia of the Alzheimer type (DAT) of mild to moderate degree. Diagnosis was ba

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ef5fbce69ce3e73a18c4e90166647ccc
https://doi.org/10.1002/(sici)1099-1077(199601)11:1<53::aid-hup761>3.0.co

Zobrazit plný text záznamu

Therapeutic drug monitoring of tacrine: simple and fast high-performance liquid chromatography assay method for its determination in human plasma

Autor: Valdo Arnera, Dietrich Hadler, Georges Anderegg, Daniel F. Chollet, Eliane Castella

Publikováno v: Therapeutic drug monitoring. 22(2)

Summary: A new high-performance liquid chromatography (HPLC) assay method was developed for the therapeutic monitoring of tacrine. The method involved a simple protein precipitation by means of either acetonitrile or cold methanol followed by a fast

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f6f403a797b11245199e088c13acf20
https://pubmed.ncbi.nlm.nih.gov/10774638

Zobrazit plný text záznamu

A randomized, double-blind, placebo-controlled phase II study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naive metastatic/unresectable non-small cell lung cancer (NSCLC)

Autor: Martin Reck, Maciej Krzakowski, Qiang Wang, Tara Fox, Dietrich Hadler, Joachim von Pawel, Jonathan Greenberg, Robert A. Beckman

Publikováno v: Journal of Clinical Oncology. 30:7536-7536

7536 Background: Tigatuzumab (T), a humanized monoclonal antibody that acts as a DR5 agonist induces apoptosis in human cancer cell lines and has shown activity in a phase 1 trial; phase 2 trials are ongoing in several tumor types. In NSCLC cells, si

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d13c82f6b44cfceb8e59b51c11ba53f7
https://doi.org/10.1200/jco.2012.30.15_suppl.7536

Zobrazit plný text záznamu

Deferasirox (Exjade®, ICL670) Treatment of Inadequately Chelated β-Thalassemia Patients from the Middle East: The ESCALATOR Trial

Autor: Shahina Daar, Amal El-Beshlawy, Ulrike Krahn, Kusai Al Zir, Dietrich Hadler, Mohsen S. El Alfy, Ali T. Taher, Abdullah Al Jefri, Ghazi Al-Damanhouri

Publikováno v: Blood. 106:3840-3840

Iron overload is a potentially life-threatening consequence of multiple blood transfusions. Effective iron chelation therapy reduces morbidity and saves lives. Many patients are unable to comply with current treatments, deferoxamine (DFO) or deferipr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eb9dada17f8c4fc33ad7586fb9405951
https://doi.org/10.1182/blood.v106.11.3840.3840

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání